International Journal of Hematology and Oncology 2022, Vol 32, Num 4 Page(s): 196-203
HYPERCOAGULABILITY AND HYPERFIBRINOLYSIS IN LUNG CANCER

MUSTAFA ÇETİN1, ALİ ÜNAL1, METİN EKİCİ1, BÜLENT ESER1, MEVLÜDİYE KAYABALİ1, HASAN S. COŞKUN1, MUSTAFA ALTINBAŞ1, ÖZLEM ER1

Erciyes Üniversitesi Tıp Fakültesi, Hematoloji-Onkoloji Bilim Dalı, KAYSERİ

Keywords: lung cancer, hipercoagulability, hiperfibrinolysis
Thromboembolic events due to activation of coagulation and hemorrhagic complications related to fibrinolytic activation were reported in lung cancer. In this study, the relation between coagulation and fibrinolytic system parameters and stage of disease were investigated in lung cancer patients. Between March 1998 and March 1999, 59 patients, 51 male and 8 female mean age of 60.77±8.00 years (range 40 - 73) with lung cancer followed in Erciyes University Faculty of Medicine Hematology-Oncology Department were studied on admission. Thirty individuals with no significant difference in age and sex were used as control group. Venous blood samples arc taken from patients and control subjects and platelet number, PT, PTT, fibrinogen, PC, PS. APC, FDP and DD levels were measured. There was no statistically significant difference in platelet number between patient and control group (p>0.05). The values of the PT, PTT, fibrinogen, PC, PS, APC-R and FDP-DD in the patient group were statistically significant increased (p<0.05). There was no statistically significant difference in platelet, PTT, fibrinogen, PC and Ps levels between extensive and limited disease in SCLC (p<0.05). Increase in PT levels and APC-R were statistically significant in extensive disease group (p<0.05). Advanced stage group of NSCL patients showed higher level of the PT, PTT. fibrinogen, APC-R, PC and PS than the early stage group (p<0.05). Levels of the FDP-DD were high in early stages of SCLC and NSCLC and showed increment in parallel to progression of the lung cancer (p<0.05). As a result, this study showed that there are coagulation activation and low degree DIG in lung cancer patients. Subclinical coagulation abnormalities and activation of fibrinolytic system in early stage lung cancer increase with progression of disease.